Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tilia americana pollen is an allergen extract derived from the pollen of the American basswood or American linden tree. It is primarily utilized as a diagnostic agent in clinical allergy testing, such as skin prick tests or intradermal tests, to identify hypersensitivity in patients suspected of having seasonal allergic rhinitis or asthma triggered by this specific tree species. The extract contains the allergenic proteins native to the Tilia americana species, which, upon exposure to the skin of a sensitized individual, cross-link IgE antibodies on mast cells and basophils. This interaction triggers the release of histamine and other inflammatory mediators, leading to a localized wheal-and-flare reaction that serves as a positive indicator of allergic sensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tilia americana pollen.